[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Soochow University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":200},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,84,115,141,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100625274","a-longitudinal-study-of-parental-sleep-intervention-for-behavioral-insomnia-in-early-childhood-100625274",false,"NCT07420504","A Longitudinal Study of Parental Sleep Intervention for Behavioral Insomnia in Early Childhood","Efficacy of Parental Sleep Intervention on Infants and Toddlers With Behavioural Insomnia: A Longitudinal Follow-up Study","SuSleep","Inclusion Criteria:\n\n1. Children aged 0-3 years.\n2. Diagnosed with behavioural insomnia.\n3. Parental consent for participation.\n\nExclusion Criteria:\n\n1. Chronic diseases or history of head trauma.\n2. Other primary sleep disorders (e.g., OSA, narcolepsy, restless leg syndrome).\n3. Developmental delay, epilepsy, or other neurological\u002Fmetabolic disorders.","ALL","6 Months","36 Months",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The global incidence of mental illness among children and adolescents is rising, drawing increasing attention to early risk factors and preventive strategies. Behavioral sleep problems, which affect up to 50% of infants in the local population, are closely linked to impaired self-regulation-a core factor underlying many psychological disorders and a promising target for early intervention. Enhancing self-regulation may not only alleviate sleep problems but also mitigate long-term mental health risks. This study aims to develop an intervention toolkit based on current guidelines and high-quality evidence, integrating parent education with dynamic sleep assessment and longitudinal evaluation of self-regulation in infants. The project seeks to establish the efficacy of this approach, identify moderators of intervention outcomes, and provide an evidence base for personalized sleep interventions in clinical practice.",[28],"Behavioural Insomnia of Childhood",[30,31,32,33,34],"infant","sleep intervention","clinical cohort","toddler","self-regulation","NOT_YET_RECRUITING","2026-02-11",{"date":38,"type":39},"2026-02-19","ACTUAL",{"date":41,"type":22},"2026-03-20",{"date":43,"type":22},"2027-12-31",{"name":45,"class":46},"Children's Hospital of Soochow University","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100581431","observational-study-on-the-impact-of-obstructive-sleep-apnea-on-executive-function-and-empathy-development-in-children-100581431","NCT06850220","Observational Study on the Impact of Obstructive Sleep Apnea on Executive Function and Empathy Development in Children","OSA-EFED","Inclusion Criteria:\n\n* Children aged 3-12 years.\n* Diagnosed with OSA due to adenoid and\u002For tonsillar hypertrophy.\n* IQ ≥ 85.\n* Parental consent for participation.\n\nExclusion Criteria:\n\n* Other primary sleep disorders (e.g., narcolepsy, restless leg syndrome).\n* Developmental delay, epilepsy, or other neurological\u002Fmetabolic disorders.\n* Chronic diseases or history of head trauma.",true,"3 Years","12 Years",{"count":58,"type":22},150,"OBSERVATIONAL","This study aims to investigate the effects of obstructive sleep apnea (OSA) on executive function and empathy development in children aged 3-12 years. The study will compare the outcomes of different treatment approaches (surgical vs. pharmacological) in children with mild OSA and track the progression of cognitive and emotional functions over 12 months. The study will also explore potential EEG biomarkers for assessing neurological damage in OSA children.",[62,63,64,65],"Pediatric Obstructive Sleep Apnea","Cognition","Empathy","EEG",[67,68,64,69,70,71,72,73],"Obstructive Sleep Apnea","Executive Function","Children","EEG Biomarkers","Cohort Study","Neurodevelopment","Adenotonsillectomy","RECRUITING","2026-01-23",{"date":77,"type":39},"2026-01-26",{"date":79,"type":39},"2025-10-13",{"date":81,"type":22},"2027-06-30",{"name":45,"class":46},1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":54,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100607109","effectiveness-of-school-based-time-restricted-eating-for-the-prevention-and-control-of-obesity-in-children-100607109","NCT07184281","Effectiveness of School-Based Time-Restricted Eating for the Prevention and Control of Obesity in Children","Effectiveness of School-Based Time-Restricted Eating for the Prevention and Control of Obesity in Children: A Cluster-Randomized Controlled Trial","SCHOOL-TRE","Eligibility criteria for schools:\n\n1. The principal agrees to accept the randomization process and adhere to the study protocol;\n2. The total number of fourth-year students in the school must be more than 50;\n3. Schools that have not implemented or plan to implement obesity prevention interventions;\n4. Non-boarding schools, Ethnic minority schools, or specialty schools;\n5. Schools that have no clear plans to relocate or close within the next 2 years;\n\nEligibility criteria for classes:\n\n1. Class teachers are willing and actively involved in home-school liaison;\n2. Class sizes should be between 30 and 60 students;\n3. The class consists of fourth-grade students;\n4. Classes that have no clear plan to merge or cancel in the next 2 years;\n\nExclusion criteria for students:\n\nAll students in the selected classes will be the subject of the study after signing the informed consent, unless they have the following circumstances:\n\n1. Individuals with a history of heart disease, high blood pressure, diabetes, tuberculosis, asthma, hepatitis or nephritis;\n2. Individuals with secondary obesity: obesity due to endocrine disorders or side effects of medications;\n3. Individuals with abnormal growth and development, such as dwarfism, gigantism, etc;\n4. Individuals with physical deformities, including severe scoliosis, chicken breasts, claudication, significant O-leg\u002FX-shaped legs;\n5. Individuals with limited athletic ability who are unable to participate in school physical activities;\n6. Individuals who have lost weight by inducing vomiting or taking medication in the past 3 months;\n7. Individuals who have undergone prior bariatric surgery;\n8. Individuals with mental disorders or intellectual developmental disabilities, as well as aphasia;\n9. Individuals who have taken medications that affect appetite or weight within three months (e.g., antipsychotics, hypnotics, weight loss medications, insulin);\n10. Individuals who have plans to transfer within 2 years;","8 Years","10 Years",{"count":95,"type":22},1380,[25],"Childhood obesity has become a major global public health challenge. Obesity can not only affects children's physical and mental health during childhood but may also persist into adulthood, significantly increasing the risk of cardiovascular disease. Therefore, effective prevention and control of childhood obesity can shift the prevention window forward and promote the prevention of cardiovascular disease. Recently, time-restricted eating (TRE) has gained attention in adult studies for its feasibility, as it involves \"time control without calorie restriction,\" demonstrating weight loss effects comparable to energy restriction and higher feasibility. Here, the investigators designed a school-based cluster randomized controlled trial to investigate the effectiveness of 12-hour TRE in preventing and controlling childhood obesity. Schools were randomly assigned to either the intervention group or the control group, and participants were recruited from each school at the class level, ensuring that each group included at least 690 children. The control group received routine health education, while the intervention group received 12-hour TRE in addition to routine health education. After a 9-month intervention period (one academic year), the two groups will be compared in terms of weight management and childhood obesity prevalence.",[99,100],"Childhood Obesity","Childhood Obesity Pevention",[102,103,104,105],"childhood obesity","school-based intervention","time-restricted eating","cluster randomized trial","2025-09-28",{"date":108,"type":39},"2025-09-30",{"date":110,"type":39},"2025-09-26",{"date":112,"type":22},"2027-07-31",{"name":45,"class":46},2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100579665","peginterferon--2b-injection-for-the-treatment-of-pediatric-rsv-bronchiolitis-100579665","NCT06827249","Peginterferon α-2b Injection for the Treatment of Pediatric RSV Bronchiolitis","A Multicenter, Randomized, Positive-controlled, Non-inferiority Clinical Study to Evaluate the Safety and Efficacy of Peginterferon α2b Injection in the Treatment of Pediatric RSV Bronchiolitis","Inclusion Criteria:\n\n1. The guardian of the child is able to understand the content, requirements, and limitations of the protocol, fully understands the possible adverse reactions that may occur during the study, is willing to complete the follow-up as required, and voluntarily signs the informed consent form before the start of the study.\n2. The child's age is 6 months or older but no more than 2 years old (including the critical value) at the time of signing the informed consent, and the gender is not specified.\n3. Positive viral detection in nasopharyngeal swab.\n4. Presence of rapid breathing, wheezing, moist rales and\u002For wheezing sounds in the lungs; with or without chest imaging showing signs of hyperinflation, patchy infiltrates, localized atelectasis, and peribronchitis.\n5. The severity of the illness is mild or moderate (evaluation criteria see Appendix 1: Wang Bronchiolitis Scoring Standard).\n6. The time from the onset of the child's illness to the signing of the informed consent form is within 72 hours (the appearance of symptoms and signs related to RSV bronchiolitis does not exceed 72 hours from the signing of the informed consent, including but not limited to: tachypnea, wheezing, hypoxemia, dyspnea, fever).\n7. No use of other antiviral drugs or immunomodulators within 3 weeks before randomization.\n\nExclusion Criteria:\n\n1. Extreme restlessness, drowsiness, coma, and possibly requiring mechanical ventilation assistance for breathing.\n2. Presence of other chronic severe diseases such as cardiac insufficiency, respiratory insufficiency, liver insufficiency, renal insufficiency, and severe malnutrition.\n3. Having autoimmune diseases such as systemic lupus erythematosus or psoriasis, or immunodeficiency diseases.\n4. Having epilepsy or other disorders of central nervous system function.\n5. The investigator's comprehensive judgment suspects a concurrent bacterial infection.\n6. Clinical diagnosis of myocarditis or suspected myocarditis (diagnostic criteria see Appendix 2: Diagnostic Recommendations for Myocarditis in Children).\n7. Known or suspected allergy to interferon or excipients.\n8. Participation in other interventional clinical trials within 3 months prior to screening, or planning to participate in other clinical trials during the study period. (9) A history of pneumonia in the past 3 months.\n\n(10) Other conditions deemed unsuitable for inclusion by the investigator.","2 Years",{"count":124,"type":22},90,[25],"This is a multicenter, randomized, positive-controlled, non-inferiority clinical study, planning to enroll 90 children with bronchiolitis caused by respiratory syncytial virus infection, to evaluate the safety and efficacy of inhaled Peginterferon α-2b injection compared to recombinant human interferon α2b in the treatment of pediatric respiratory syncytial virus bronchiolitis.",[128],"Bronchiolitis",[128,130,131],"Peginterferon α-2b","respiratory syncytial virus","2025-02-09",{"date":134,"type":39},"2025-02-14",{"date":136,"type":22},"2025-03",{"date":138,"type":22},"2027-06",{"name":45,"class":46},3,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":153,"conditions":154,"keywords":160,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100540447","phase-2-safety-and-efficacy-of-avapritinib-in-relapsed-or-refractory-pediatric-cbf-aml-with-kit-mutation-100540447","NCT06316960","Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","A Prospective, Multicenter Clinical Study on The Safety and Efficacy of Avapritinib in The Treatment of Relapsed\u002FRefractory Pediatric Core Binding Factor Acute Myeloid Leukemia (CBF-AML) With KIT Mutation","Inclusion Criteria:\n\n1. Gender unlimited;\n2. Under 18 years;\n3. Diagnosis of acute myeloid leukemia (according to the 2022 WHO classification).\n4. Presence of t(8;21)\u002FRUNX1::RUNX1T1 or inv(16)\u002Ft(16;16)\u002FCBFβ::MYH11;\n5. KIT mutation;\n6. Refractory AML: AML patients who do not achieve CR or CRi after induction therapy;\n7. Relapsed AML: patients who achieved remission after consolidation therapy or transplantation, FISH confirmed that the fusion gene turned positive, or extramedullary leukemia infiltration;\n8. No active infections;\n9. Liver function: Tbil ≤2×ULN, ALT\u002FAST ≤3×ULN, creatinine clearance ≥50ml\u002Fmin;\n10. ECOG score \\\u003C2;\n11. Expected survival time \\>12 weeks;\n12. Participants must have the ability to understand and be willing to participate in this study and must sign an informed consent form.\n\nExclusion Criteria:\n\n1. Have received prior treatment with avapritinib;\n2. Receiving other targeted therapies for AML at the same time, such as dasatinib, sorafenib, gilteritinib, venetoclax, etc;\n3. Presence of active uncontrolled infection (including bacterial, fungal, or viral infection);\n4. Present of significant underlying organ diseases: such as myocardial infarction, chronic heart failure, decompensated liver or kidney dysfunction；\n5. With other malignancies requiring treatment；\n6. Already enrolled in another interventional clinical study；\n7. The researchers determined that the individual is not suitable to participate in this trial.","18 Years",{"count":150,"type":22},50,[152],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.",[155,156,157,158,159],"AML, Childhood","Relapse\u002FRecurrence","Refractory AML","Core Binding Factor Acute Myeloid Leukemia","C-KIT Mutation",[161,162,163,164,165],"Avapritinib","KIT","CBF AML","Childhood","Relapsed\u002FRefractory","2024-08-21",{"date":168,"type":39},"2024-08-22",{"date":170,"type":39},"2024-03-01",{"date":172,"type":22},"2027-03",{"name":45,"class":46},12,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":148,"enrollmentInfo":183,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":186,"conditions":187,"keywords":189,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},"100533120","phase-2-clinical-study-of-induction-therapy-options-based-on-molecular-subtyping-and-mrd-in-children-and-adolescents-with-aml-100533120","NCT06221683","Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","A Multicenter Clinical Study of Molecular Subtyping Combined With MRD-driven Remission Induction Regimen in Children and Adolescents With AML: A Phase II Cohort Study (GMCAII)","GMCAII","Inclusion Criteria:\n\n* 1、Newly diagnosed, untreated AML；\n* 2、Under 18 years old;\n* 3、Patients who have used hydroxyurea or cytarabine before diagnosis, but the dosage of cytarabine does not exceed 5 days, and the total dose does not exceed 500 mg\u002Fm2 (50 mg\u002Fm2, q12h × 5d)；\n* 4、 Liver function：Tbil≤2×ULN, ALT\u002FAST≤3×ULN, creatinine clearance ≥50ml\u002Fmin；Cardiac NYHA grading\\\u003C3；SaO2\\>92%;\n* 5、No active infection (symptoms resolved for more than 3 days if infected)\n* 6、ECOG\\\u003C2;\n* 7、Expected survival time greater than 12 weeks;\n* 9、Obtain the consent of the child and\u002For guardian and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1、Acute megakaryocytic leukemia (AMKL)；\n* 2、Acute promyelocytic leukemia (APL);\n* 3、Treatment-related secondary AML and AML with definite MDS transformation；\n* 4、Myeloproliferative neoplasm (such as Juvenile myelomonocytic leukemia, JMML);\n* 5、AML secondary to congenital bone marrow failure (such as AML secondary to Fanconi anemia (FA)；\n* 6、AML secondary to Down syndrome;\n* 7、Only temporary chemotherapy, radiotherapy, or immunotherapy, but not systematic treatment according to the treatment plan;\n* 8、 Temporary chemotherapy, radiotherapy, or immunotherapy only, not systemic therapy per protocol;\n* 9、Having any significant abnormal concurrent disease or mental illness that impacts the life safety and compliance of the patient and impacts informed consent, study participation, follow-up, or interpretation of results. In this case, all the participating units are required to report directly to the responsible person for this project to jointly decide whether they meet the exclusion criteria；\n* 10、Patients with very poor nutritional status, severe infection, cardiac insufficiency, and intolerance to chemotherapy;\n* 11、Relapsed AML at any time；\n* 12、The attending physician considers that the patient is not suitable for entering the study protocol based on the patient's physical condition, economic status, and other factors.",{"count":184,"type":22},500,[152],"The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR\u002FCRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular\u002Fprecision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.",[155,188],"Acute Myeloid Leukemia",[190,164,191,192],"AML","Molecular subtyping","MRD",{"date":168,"type":39},{"date":195,"type":39},"2024-01-01",{"date":197,"type":22},"2029-12",{"name":45,"class":46},13,""]